Please assess the completion status of the following clinical trial:

Trial Title: Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Eligibility Criteria~* Age: 3-21 years.~* Group 1 or Group 3: histologically proven initial diagnosis of primary malignant brain tumor, with no known curative treatment options.~* Group 2: histologically proven initial diagnosis of high-grade glioma (WHO grade III and IV), ependymoma, medulloblastoma, or other primary central nervous system tumor.~* Group 3b: Patients with a radiographic diagnosis or histologically proven diagnosis of diffuse intrinsic pontine glioma (DIPG).~* MRI confirmation of tumor progression or regrowth.~* Patients must be able to swallow whole capsules.~* Patients with metastatic disease are eligible for enrollment.~* Lansky or Karnofsky performance status score must be \> 50%.~* Seizure disorders must be well controlled on antiepileptic medication.~* DIPG patients enrolled to Group 3b must not have been previously treated with radiation or any medical therapy.~* Patients previously treated with temozolomide, cyclophosphamide, and/or etoposide are eligible for enrollment.~Exclusion Criteria~* Prior invasive malignancy, other than the primary central nervous system tumor, unless the patient has been disease free and off therapy for that disease for a minimum of 3 years~* Patients with baseline QTc interval of more than 470 msec at study entry, and patients with congenital long QTc syndrome.~* Active autoimmune disease

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (CLOSED) (Type: EXPERIMENTAL): Core Regimen: Dose-escalation of indoximod, in combination with temozolomide, for pediatric patients with progressive brain tumors.~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m\^2 x 5 days
- Group 2 (CLOSED) (Type: EXPERIMENTAL): Expansion cohorts: Indoximod therapy at the pediatric recommended phase 2 dose (RP2D) determined by Group 1, in combination with temozolomide.~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m\^2 x 5 days
- Group 3 (CLOSED) (Type: EXPERIMENTAL): Dose-escalation of indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with progressive brain tumors.~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m\^2 x 5 days
- Group 3b (Type: EXPERIMENTAL): Indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with newly diagnosed treatment-naive diffuse intrinsic pontine glioma (DIPG).~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m\^2 x 5 days
- Group 4 (Type: EXPERIMENTAL): Continued access to indoximod in combination with low-dose oral cyclophosphamide and etoposide for patients with progressive disease after treatment with indoximod plus temozolomide.~Indoximod will be administered at 32 mg/kg/dose divided twice daily.~Cyclophosphamide to be given at 2.5 mg/kg/dose daily~Etoposide to be given at 50 mg/m2/dose daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete